文献速递慢性肾脏病血液净化与透析肾移植

加速与标准乙型肝炎疫苗接种在晚期CKD患者中的随机对照研究

A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD.
PubMed 文献 · Kidney Int Rep · 2024-01-17

本研究为随机对照试验,纳入晚期CKD(eGFR<30 ml/min/1.73 m2)及透析患者,比较加速方案(0、1、4、8周接种40 μg)与标准方案(0、4、8、24周接种40 μg)的乙型肝炎疫苗效果。结果显示加速组第12周血清转换率显著高于标准组(83.08% vs 63.24%,P=0.01),第28和52周两组相似。提示加速方案可在透析或移植前快速获得血清转换。

要点

  • 加速乙肝疫苗方案在第12周血清转换率显著高于标准方案。
  • 第28和52周两组血清转换率相似。
  • 晚期CKD患者可考虑加速方案以快速获得保护。

核心结论

  • 在晚期CKD患者中,加速HBV疫苗接种方案在第12周显示出显著更高的血清转换率。
  • 加速方案是透析或肾移植前快速获得血清转换的有效选择。

研究设计与样本

  • 随机对照试验,纳入晚期CKD(eGFR<30 ml/min/1.73 m2)及透析患者。
  • 加速方案:40 μg at 0、1、4、8周;标准方案:40 μg at 0、4、8、24周。
  • ITT人群133例(加速组65例,标准组68例);PP分析125例(标准组62例,加速组63例)。

主要发现

  • 第12周ITT人群血清转换率:加速组83.08% vs 标准组63.24%,P=0.01。
  • 第12周PP分析血清转换率:加速组85.71% vs 标准组69.35%,P=0.03。
  • 第28和52周两组血清转换率相似。

关键数值与推荐

  • 血清转换定义为anti-HBs ≥10 IU/l。
  • 血清转换率在第12、28、52周测量。

临床怎么用

  • 对于晚期CKD患者,可考虑采用加速HBV疫苗接种方案以在透析或移植前快速获得血清转换。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hepatitis B virus (HBV) vaccination is crucial for seronegative patients with advanced chronic kidney disease (CKD) for protection during dialysis while preparing for transplantation. A standard regimen for HBV vaccination requires 24 weeks to be completed. An accelerated HBV vaccination regimen completed within 8 weeks has shown early effective seroconversion in healthcare workers. However, data for patients with advanced CKD are limited. METHODS: A randomized controlled trial was conducted in patients with advanced CKD (estimated glomerular filtration rate [GFR] <30 ml/min per 1.73 m2) and patients on dialysis. The patients were randomly assigned to either a standard HBV vaccination regimen (Engerix B; 40 μg at 0, 4, 8, and 24 weeks) or an accelerated regimen (40 μg at 0, 1, 4, and 8 weeks). The hepatitis B surface antibodies (anti-HBs) were measured at 12, 28, and 52 weeks. Seroconversion were defined as anti-HBs ≥10 IU/l. RESULTS: At 12 weeks, among the intention-to-treat (ITT) population of 133 participants (65 in the accelerated and 68 in the standard groups), the accelerated group demonstrated significantly higher rates of seroconversion (83.08% vs. 63.24%, P = 0.01). In the per-protocol (PP) analysis of 125 patients (62 in the standard and 63 in the accelerated groups), the accelerated group exhibited higher seroconversion rate compared with the standard group (85.71% vs. 69.35%, P = 0.03). At 28 and 52 weeks, the seroconversion rates were similar between the 2 groups. CONCLUSION: In patients with advanced CKD, the accelerated HBV vaccination regimen demonstrated a significantly higher seroconversion rate at 12 weeks of vaccination. This finding suggests that the accelerated regimen is an effective option to achieve rapid seroconversion before initiating hemodialysis or before undergoing kidney transplantation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kittrakulrat J, Tiankanon K, Kerr SJ, et al. A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD. Kidney Int Rep. 2024. PMID: 38770057. doi:10.1016/j.ekir.2024.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。